Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c03183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Kaiyong Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanji…. Hauptthemen laut MEDLINE: Janus Kinase 1, Protein Kinase Inhibitors. Die Arbeit nennt 57 Literaturangaben. Gefördert von: China Pharmaceutical University, Science Fund for Distinguished Young Scholars of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Janus kinase 1 (JAK1)-preferential inhibition has emerged as a promising approach to maintain anti-inflammatory efficacy while minimizing hematopoietic adverse effects attributed to JAK2 blockade. Guided by a design concept aiming for sufficient JAK1 target engagement without excessive pathway suppression, we designed and optimized a series of imidazopyrrolopyridines to identify compound 40 (YYSW001). YYSW001 exhibited potent JAK1 inhibition (IC50 = 6 nM) with >50-fold selectivity over JAK2 and strong cellular activity. Pharmacokinetic evaluation revealed 61.8% oral bioavailability. In rat collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models, YYSW001 demonstrated therapeutic efficacy comparable to upadacitinib. Consistent with its JAK1/JAK2 selectivity, YYSW001 reduced JAK2-associated liabilities, including hematologic dysfunction and weight loss, relative to upadacitinib. Overall, YYSW001 represents a preferential JAK1 inhibitor with a favorable efficacy-tolerability profile, which is currently undergoing preclinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China.
- Yiyou Biotech (Shanghai) Co., Ltd, Shanghai 201306, P. R. China.
- Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, P. R. China.
ORCID-Profile: Pengfei Xu, Zhiyu Li, Zhixia Qiu, Jinlei Bian
Förderung
- China Pharmaceutical University
- Science Fund for Distinguished Young Scholars of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Hu, K., Wang, Y., Xu, P., Jing, T., Cheng, X., Shen, P., Wang, B., Fu, K., Zhang, M., Gao, M., Li, Z., Wang, J., Qiu, Z., & Bian, J. (2026). Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03183
Vancouver
Hu K, Wang Y, Xu P, Jing T, Cheng X, Shen P, et al. Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03183
BibTeX
@article{Hu2026,
author = {Hu, Kaiyong and Wang, Yezhi and Xu, Pengfei and Jing, Tian and Cheng, Xinying and Shen, Pei and Wang, Baoxin and Fu, Kang and Zhang, Min and Gao, Mingjing and Li, Zhiyu and Wang, Jubo and Qiu, Zhixia and Bian, Jinlei},
title = {Discovery of YYSW001: A Highly Selective, Orally Bioavailable JAK1 Inhibitor Achieving Efficacy under a Moderate-Inhibition Strategy with Improved Preclinical Tolerability},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c03183}
}
EUVIMED